Li Watsek
Stock Analyst at Cantor Fitzgerald
(0.28)
# 4,451
Out of 4,644 analysts
119
Total ratings
42.6%
Success rate
-7.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintained: Buy | $300 | $255.46 | +17.44% | 25 | Aug 6, 2026 | |
| ZLAB Zai Lab | Maintained: Buy | $37 | $25.49 | +45.15% | 9 | Aug 6, 2026 | |
| REPL Replimune Group | Upgraded: Buy | n/a | $15.24 | - | 6 | Jul 31, 2026 | |
| ANL Adlai Nortye | Maintained: Buy | n/a | $13.09 | - | 2 | Jul 16, 2026 | |
| IMRX Immuneering | Initiated Coverage: Buy | $17 | $5.07 | +235.31% | 1 | Jul 8, 2026 | |
| FTH Faeth Therapeutics | Maintained: Buy | n/a | $29.38 | - | 2 | Jun 3, 2026 | |
| CRIS Curis | Rated: Hold | n/a | $1.67 | - | 4 | Mar 27, 2026 | |
| TYRA Tyra Biosciences | Maintained: Buy | n/a | $25.30 | - | 2 | Mar 4, 2026 | |
| AVBP ArriVent BioPharma | Initiated Coverage: Buy | n/a | $31.46 | - | 1 | Dec 22, 2025 | |
| CMPX Compass Therapeutics | Initiated Coverage: Buy | n/a | $2.37 | - | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $28.96 | - | 6 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.4699 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.87 | - | 6 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $36.96 | - | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.94 | n/a | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $15.05 | n/a | 8 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.72 | n/a | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.89 | n/a | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.01 | n/a | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.06 | n/a | 5 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $0.18 | n/a | 4 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $2.72 | n/a | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $5 | $0.0127 | n/a | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $71 → $38 | $2.39 | n/a | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $6 | $11.77 | n/a | 3 | Jun 28, 2022 |
Ascendis Pharma
Aug 6, 2026
Maintained: Buy
Price Target: $300
Current: $255.46
Upside: +17.44%
Zai Lab
Aug 6, 2026
Maintained: Buy
Price Target: $37
Current: $25.49
Upside: +45.15%
Replimune Group
Jul 31, 2026
Upgraded: Buy
Price Target: n/a
Current: $15.24
Upside: -
Adlai Nortye
Jul 16, 2026
Maintained: Buy
Price Target: n/a
Current: $13.09
Upside: -
Immuneering
Jul 8, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $5.07
Upside: +235.31%
Faeth Therapeutics
Jun 3, 2026
Maintained: Buy
Price Target: n/a
Current: $29.38
Upside: -
Curis
Mar 27, 2026
Rated: Hold
Price Target: n/a
Current: $1.67
Upside: -
Tyra Biosciences
Mar 4, 2026
Maintained: Buy
Price Target: n/a
Current: $25.30
Upside: -
ArriVent BioPharma
Dec 22, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $31.46
Upside: -
Compass Therapeutics
Dec 3, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $2.37
Upside: -
Oct 8, 2025
Reiterated: Buy
Price Target: n/a
Current: $28.96
Upside: -
Oct 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $0.4699
Upside: -
Sep 18, 2025
Reiterated: Buy
Price Target: n/a
Current: $8.87
Upside: -
Sep 9, 2025
Reiterated: Buy
Price Target: n/a
Current: $36.96
Upside: -
Jun 26, 2025
Reiterated: Buy
Price Target: n/a
Current: $9.94
Upside: n/a
Jun 12, 2025
Reiterated: Buy
Price Target: n/a
Current: $15.05
Upside: n/a
May 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $1.72
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Mar 14, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $3.89
Upside: n/a
Jan 24, 2025
Reiterated: Buy
Price Target: n/a
Current: $2.01
Upside: n/a
Jun 3, 2024
Reiterated: Buy
Price Target: n/a
Current: $4.06
Upside: n/a
Aug 30, 2023
Maintained: Buy
Price Target: $11
Current: $0.18
Upside: n/a
Aug 9, 2023
Reiterated: Hold
Price Target: $5
Current: $2.72
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: $8 → $5
Current: $0.0127
Upside: n/a
Aug 12, 2022
Maintained: Buy
Price Target: $71 → $38
Current: $2.39
Upside: n/a
Jun 28, 2022
Maintained: Buy
Price Target: $16 → $6
Current: $11.77
Upside: n/a